Neuraptive Therapeutics, Inc. Strengthens its Board of Directors With Appointment of Cary Sucoff, J.D.
Slightly above 67% of ContraFect Corp's investor base is looking to short. The analysis of current outlook of investing in ContraFect Corp suggests that many traders are alarmed regarding ContraFect Corp's prospects. ContraFect Corp's investing sentiment can be driven by a variety of factors including economic data, ContraFect Corp's earnings reports, geopolitical events, and overall market trends.
ContraFect |
Neuraptive Therapeutics, Inc., a biotechnology company dedicated to developing novel therapeutics and medical products to address the unmet needs of p
Read at businesswire.com
 |
ContraFect Corp Fundamental Analysis
We analyze ContraFect Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ContraFect Corp using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ContraFect Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Debt
Total Debt Comparative Analysis
ContraFect Corp is currently under evaluation in total debt category among its peers. Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
ContraFect Corp Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with ContraFect Corp stock to make a market-neutral strategy. Peer analysis of ContraFect Corp could also be used in its relative valuation, which is a method of valuing ContraFect Corp by comparing valuation metrics with similar companies.
Peers
ContraFect Corp Related Equities
| CNSP | Cns Pharmaceuticals | 27.27 | ||||
| UNCY | Unicycive Therapeutics | 5.36 | ||||
| DRMA | Dermata Therapeutics | 5.31 | ||||
| REVB | Revelation Biosciences | 2.88 | ||||
| VRAX | Virax Biolabs | 1.06 | ||||
| PALI | Palisade Bio | 0.97 | ||||
| ALLR | Allarity Therapeutics | 2.97 | ||||
| QNRX | Quoin Pharmaceuticals | 6.06 | ||||
| WINT | Windtree Therapeutics | 6.67 |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Other Consideration for investing in ContraFect Stock
If you are still planning to invest in ContraFect Corp check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ContraFect Corp's history and understand the potential risks before investing.
| CEOs Directory Screen CEOs from public companies around the world | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |